Maike Tian Plunges 43% on Hong Kong Debut, Marking Weakest IPO of 2026
Crhk · 2 SOURCESabout 2 hours ago2 MIN
Summary
Maike Tian, a mainland Chinese medical device provider listed under stock code 02041 on the Hong Kong Stock Exchange, suffered a dramatic first-day decline on Monday, September 7, closing nearly 43 percent below its IPO price. The stock opened weak and never recovered, leaving many retail investors who secured shares facing substantial paper losses. Despite overwhelming retail demand during the subscription period, the listing failed to sustain investor interest, raising concerns about market sentiment toward the healthcare sector.
Key Points
- Maike Tian closed at HK$8.8 on Monday, representing a 42.9 percent loss from its listing price of HK$15.42, with investors incurring approximately HK$662 in paper losses per 100-share lot .
- The stock tumbled as low as HK$9.99 during the session, a 35.2 percent drop from the IPO price, before recovering slightly to trade at HK$10.37 by afternoon, still down 32.7 percent .
- Hong Kong retail investors demonstrated exceptional enthusiasm, with the public offering subscription reaching 436.37 times oversubscribed, resulting in a winning rate of just 5 percent for applicants .
- The international placing attracted more modest interest at 2.35 times oversubscribed, suggesting institutional investors were less enthusiastic about the deal compared to retail participants .
- Maike Tian raised net proceeds of HK$496 million through the global offering of 38.91 million shares, with the Hong Kong public tranche accounting for 10 percent of total shares .
Why It Matters
The sharp debut decline of Maike Tian highlights a growing disconnect between retail subscription fever and actual market performance, suggesting that oversubscribed IPOs do not guarantee post-listing success. This outcome may prompt Hong Kong Exchange officials and listing applicants to reassess valuation expectations, particularly in the healthcare and medical device sectors where fundamentals face heightened scrutiny amid economic uncertainty .
The sharp debut decline of Maike Tian highlights a growing disconnect between retail subscription fever and actual market performance, suggesting that oversubscribed IPOs do not guarantee post-listing success. This outcome may prompt Hong Kong Exchange officials and listing applicants to reassess valuation expectations, particularly in the healthcare and medical device sectors where fundamentals face heightened scrutiny amid economic uncertainty .